Analytical Data
-
Gene name
SLC25A13
- Application
-
Alternative Names
ARALAR2; Citrin; Mitochondrial Aspartate Glutamate Carrier 2; Calcium-binding mitochondrial carrier protein Aralar2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UJS0
-
Expression Region
Ala326~Trp606
-
Molecular Weight
34.0kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC25A13, a member of the solute carrier family, encodes a mitochondrial carrier protein crucial for the transport of metabolites across the mitochondrial membrane, specifically in the context of the urea cycle and amino acid metabolism. Deficiencies in SLC25A13 have been linked to a rare genetic disorder known as citrin deficiency, which can lead to severe metabolic disturbances, including hyperammonemia and fatty liver disease. The investigation of SLC25A13 recombinant proteins has emerged as a critical area of research to elucidate the functional dynamics of this transporter, its interaction with various substrates, and the underlying mechanisms governing its activity. By expressing and purifying recombinant SLC25A13 in heterologous systems, researchers aim to perform in vitro studies that assess the protein's transport capabilities and structural properties. Such studies can provide insights into the pathophysiological implications of SLC25A13 mutations and may facilitate the development of targeted therapeutic strategies. Understanding how SLC25A13 functions not only contributes to the broader field of mitochondrial biology and metabolic disease but also holds potential for advancing personalized medicine approaches in treating disorders associated with dysfunctional mitochondrial transport.
